 |
PRESS
RELEASES 
|
Press Release
MOLOGEN plans to move up to Prime Standard
· Day of first trading planned within the next two months · Aims: broadening of the shareholder base and increase in share liquidity Berlin, 28 May 2009. Mologen AG is planning a segment switch to the Prime Standard. The company submitted the application for this to Frankfurt Stock Exchange today.
The company's shares have been traded in the General Standard on the Regulated Market at Frankfurt Stock Exchange up to now. They are to be admitted to the part of the Regulated Market at Frankfurt Stock Exchange in which additional requirements have to be met (Prime Standard). The application relates to all 9 803 348 ordinary bearer shares with no par value. Following the switch to the Prime Standard, Mologen AG will be listed in the stock market segment in which Deutsche Börse makes the highest transparency and disclosure requirements. Listing in the Prime Standard is also essential for inclusion in one of Deutsche Börse's specialised indices.
Dr Matthias Schroff, Chairman of the Executive Board of Mologen AG: "Our aims in switching to the Prime Standard are to increase share liquidity and to make the share more attractive to investors because of the increase in transparency, in order to broaden our shareholder base. This step is in addition the logical response to the positive interest in the Mologen share shown by the capital market."
About MOLOGEN
MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes in the research and development of innovative medicines based on DNA structures (DNA: deoxyribonucleic acid).
Its patented DNA-based technology platforms MIDGE® and dSLIM® form a universal foundation with a wide range of possible applications. Activities focus on product developments for the treatment of cancer and vaccines for serious infections in humans and animals.
MOLOGEN was founded in 1998 and was the first German biotechnology company to go public. MOLOGEN AG shares are listed in the General Standard of Deutsche Börse (ISIN DE 0006637200).
Disclaimer concerning prognoses
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.
|
|
